Insider trade

Karah Herdman Parschauer, Officer at Ultragenyx Pharmaceutical, sold ~$76K of Ultragenyx Pharmaceutical shares.

~$76K
Approx. value · 2,450 sh @ $31.17
73K
Holds after · shares reported
Traded
Sep 12, 2025
Filed
Sep 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 15, 2025CongressDisclosed purchase of RARE — reported range $1,001 - $15,000
  2. Aug 8, 2025CongressDisclosed purchase of RARE — reported range $1,001 - $15,000
  3. Sep 5, 2025InsiderOfficer sold ~$2.6K of RARE shares in the open market
  4. Sep 12, 2025 · this disclosureInsiderOfficer sold ~$76K of RARE shares in the open market

What came next

  1. Sep 18, 2025InsiderOfficer sold ~$1.9K of RARE shares in the open market
  2. Nov 3, 2025Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Ultragenyx Pharmaceutical

For Ultragenyx Pharmaceutical, OQRO holds 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its RARE page.

Other recent filings by Karah Herdman Parschauer, EVP and Chief Legal Officer

The full history of Karah Herdman Parschauer, EVP and Chief Legal Officer is on the profile page.

How this filing works

Other disclosures at Ultragenyx Pharmaceutical

Everything OQRO holds on this company is on its RARE page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data